On November 3, 2025, HiLung Director / Head of Translational Science Toshio Suzuki delivered a lecture at the 38th Annual Meeting of the Japanese Society for Alternatives to Animal Experiments, held at Pacifico Yokohama (program link: https://jsaae38.secand.net/img/program_20251002.pdf ).
The presentation, titled “Bridging Animal–Human Translational Gaps in Respiratory Safety Pharmacology via Complementary Testing with Human iPSC-Derived Lung Organoids,” highlighted critical limitations of conventional animal-based respiratory safety testing and demonstrated how human-relevant organoid platforms can address key species-difference issues.
HiLung applies its lung organoid technologies not only to efficacy and pharmacology studies but also extensively to respiratory safety pharmacology. We are actively engaged in numerous collaborative and contract research projects with partners in Japan and abroad.
As a company dedicated to advancing New Approach Methodologies (NAMs), HiLung continuously evolves its platform to become a next-generation standard for human-relevant respiratory evaluation.